Back to Cell Types

HT-3Homo sapiens (Human)Cancer cell line

Also known as: HT3

🤖 AI SummaryBased on 10 publications

Quick Overview

Human cervical carcinoma cell line with HPV-negative status and pRB mutations.

Detailed Summary

HT-3 is a human cervical carcinoma cell line derived from a cervical cancer tumor. It is HPV-negative, meaning it does not contain human papillomavirus (HPV) DNA. This cell line is characterized by mutations in the RB1 gene, which encodes the retinoblastoma protein (pRB). These mutations lead to the inactivation of pRB, a key tumor suppressor protein involved in cell cycle regulation. Additionally, HT-3 exhibits mutations in the TP53 gene, which encodes the p53 protein, another critical tumor suppressor. The presence of these mutations suggests that HT-3 is a valuable model for studying the molecular mechanisms of cervical cancer progression and the role of pRB and p53 in tumorigenesis. HT-3 has been used in studies investigating the effects of HPV on cancer development and the identification of genetic alterations associated with cervical cancer.

Research Applications

Study of HPV-negative cervical cancer mechanismsInvestigation of RB1 and TP53 mutations in tumorigenesisAnalysis of genetic alterations in cervical cancer progression

Key Characteristics

HPV-negative statusRB1 gene mutationsTP53 gene mutations

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1293
Species	Homo sapiens (Human)
Tissue Source	Lymph node[UBERON:UBERON_0000029]

Donor Information

Age	58
Age Category	Adult
Sex	Female

Disease Information

Disease	Cervical carcinoma
Lineage	Cervix
Subtype	Cervical Adenocarcinoma
OncoTree Code	CEAD

DepMap Information

Source Type	ATCC
Source ID	ACH-001525_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Gly245Val (c.734G>T)	Unspecified	-	PubMed=20557307

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D13S317

12

D16S539

12,13

D18S51

15

D19S433

14

D21S11

29

D2S1338

21

D3S1358

15

D5S818

10,13

D7S820

8,10

D8S1179

13,14

FGA

21,22

Penta D

12

Penta E

11,12

TH01

6,7

TPOX

8

vWA

15,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Oncotarget 8:86369-86383(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Individual karyotypes at the origins of cervical carcinomas.";

Duesberg P.H.

Mol. Cytogenet. 6:44.1-44.23(2013).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Smad4 deficiency in cervical carcinoma cells.";

Schwarte-Waldhoff I.

Oncogene 24:810-819(2005).

Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.

DiMaio D.

Cell Growth Differ. 10:413-422(1999).

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

Polymorphic enzyme analysis of cultured human tumor cell lines.";

Dracopoli N.C., Fogh J.

J. Natl. Cancer Inst. 70:469-476(1983).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Am. J. Pathol. 119:361-366(1985).

The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Scheffner M., Munger K., Byrne J.C., Howley P.M.

Proc. Natl. Acad. Sci. U.S.A. 88:5523-5527(1991).

Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.

Kerbel R.S., Pross H.F., Leibovitz A.

Int. J. Cancer 20:673-679(1977).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue Antigens 11:279-286(1978).

New human tumor cell lines.";

Fogh J., Trempe G.L.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York; USA (1975).

Web Resources